US pharma major AbbVie (NYSE: ABBV) has announced a deal with Xilio Therapeutics (Nasdaq: XLO), more than doubling the latter’s share price.
The collaboration and option-to-license agreement is for the development of novel tumor-activated, antibody-based immunotherapies, including masked T-cell engagers, using Xilio's technology.
Xilio is advancing a pipeline of novel, clinical and pre-clinical immunotherapies, including masked multispecific molecules designed to achieve tumor-selective activation by using masking and other unique components that are optimized for the specific target.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze